Want to join the conversation?
$KELYA $KELYB said EMEA had year-over-year revenue growth of 3% in 2Q16 compared to 2Q15. Commercial revenue was up 3% and PT revenue was up 2%, both coming from growth in the majority of markets. The growth was partially offset by lower volumes in Russia, the Nordics and the UK. Fee-based income was up 12% year-over-year.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.